Steve Eisman on the 'Paradigm Shift' Happenin...

You probably already know someone doing peptides — the amino acids that form the basis of popular new drug treatments like Ozempic and Wegovy. Today there are peptides meant to help with everything from weight loss, to cellular regeneration, to improved eye contact while talking. ...  Afficher plus

The politics of AI are already exploding. Whether we're talking about data centers, electricity prices, labor displacement, water consumption, competition with China, or users of chatbots becoming psychotically obsessed, AI is already a major topic in elections. And since there's ...  Afficher plus

Carl Quintanilla, Jim Cramer and David Faber led off the show with a look at the markets and how the decline in yields is impacting big and small investors alike. Stocks that are part of the reopening trade in focus as the COVID Delta variant continues to spread and the pace of v ...  Afficher plus

Tom welcomes back Tony Greer from the Morning Navigator to delve into the various market trends and investment strategies. Greer, who is bullish on gold, S&P, industrial miners, and uranium, while bearish on bonds, shares his perspective on the current economic climate. He refere ...  Afficher plus

The Dow closed up a marginal 3 points and Jim Cramer is guiding investors through what he calls "The Gauntlet" of earnings season. Then, Centene CEO Michael Neidorff is digging deeper into earnings and what caused the stock to fall today despite seemingly strong headlines. Plus, ...  Afficher plus

CNBC's Bob Pisani spoke with Mel Faber, Co-founder and CIO of Cambria Investments along with Tom Lydon, Global CEO of ETF Trends. They discussed what to do in a down market without taking yourself out of the game entirely – whether it’s momentum trading or put options. Plus, what ...  Afficher plus